Cross Talk Between the Renin-Angiotensin-Aldosterone System and Vitamin D-FGF-23-klotho in Chronic Kidney Disease

Martin H. de Borst,* Marc G. Vervloet,† Piet M. ter Wee,† and Gerjan Navis*

*Department of Internal Medicine, Division of Nephrology, University Medical Center Groningen and University of Groningen, The Netherlands; and †Department of Nephrology, Vrije Universiteit Medical Center, Amsterdam, The Netherlands

ABSTRACT

There is increasingly evidence that the interactions between vitamin D, fibroblast growth factor 23 (FGF-23), and klotho form an endocrine axis for calcium and phosphate metabolism, and derangement of this axis contributes to the progression of renal disease. Several recent studies also demonstrate negative regulation of the renin gene by vitamin D. In chronic kidney disease (CKD), low levels of calcitriol, due to the loss of 1-alpha hydroxylase, increase renal renin production. Activation of the renin-angiotensin-aldosterone system (RAAS), in turn, reduces renal expression of klotho, a crucial factor for proper FGF-23 signaling. The resulting high FGF-23 levels suppress 1-alpha hydroxylase, further lowering calcitriol. This feedback loop results in vitamin D deficiency, RAAS activation, high FGF-23 levels, and renal klotho deficiency, all of which associate with progression of renal damage. Here we examine current evidence for an interaction between the RAAS and the vitamin D-FGF-23-klotho axis as well as its possible implications for progression of CKD.


The renin-angiotensin-aldosterone system (RAAS) plays a pivotal role in renal progression and its complications. Accordingly, RAAS blockade has been the cornerstone of renoprotective interventions. Vitamin D deficiency is traditionally recognized as a key factor in the bone and mineral disturbances of chronic kidney disease (CKD), and vitamin D supplementation is standard treatment for many renal patients. As reviewed elsewhere, vitamin D interacts with the more recently identified moieties, fibroblast growth factor 23 (FGF-23) and klotho. As such, vitamin D, FGF-23, and klotho represent an endocrine axis involved in the regulation of calcium and phosphate metabolism.

Besides having effects on mineral metabolism, vitamin D deficiency is also associated with progressive renal disease and with mortality in chronic kidney disease (CKD). In line with these observations, the use of vitamin D analogues may provide with a survival advantage in dialysis patients, and preclinical and clinical data indicate that vitamin D analogues have additional renoprotective effects in addition to RAAS blockade, supporting their clinical relevance. Multiple mechanisms are likely involved in the protective effects of vitamin D, including autocrine anti-inflammatory and antifibrotic effects, as well as a suppressive effect on the RAAS. Several lines of evidence support the impact of vitamin D on RAAS activity at the clinical, pathophysiological, and molecular level. The other way round, RAAS activity influences the vitamin D-FGF-23-klotho axis. Recent studies show that angiotensin II reduces renal expression of klotho, which, in turn, modulates FGF-23-signaling and 1-alpha hydroxylase, the enzyme converting calcidiol to calcitriol. As derangement of the vitamin D-FGF-23-klotho axis associates with cardiovascular complications in several studies, the interactions of this axis with the RAAS may have therapeutic implications in CKD patients, regarding both renal and cardiovascular outcomes.

MODULATION OF THE RAAS BY VITAMIN D

The first clinical studies suggesting an inverse relationship between calcitriol and renin levels were published two decades ago and were recently confirmed in a large cohort study. Vitamin D deficiency, defined as calcidiol levels below 15 ng/ml, associates with reduced renal plasma flow responses to infused angiotensin II, suggesting endogenous intrarenal RAAS activation in vitamin D deficient subjects, and intervention with calcitriol decreases plasma renin and angiotensin II levels in hemodialysis patients with secondary hyperparathyroidism.
Several mechanistic studies confirming negative regulation of the renin gene by calcitriol have been published by the group of Li et al., who demonstrated increased renin gene expression in kidneys of vitamin D receptor (VDR) null mice, accompanied by increased plasma angiotensin II levels, hypertension, and cardiac hypertrophy. In wild-type mice, conversely, treatment with calcitriol reduces renal renin production. The negative regulation of renin by calcitriol seems independent of calcium and PTH. On a molecular level, renin by calcitriol seems independent of production. The negative regulation of renin with calcitriol reduces renal renin production. The negative regulation of renin during therapy, can hamper its therapeutic efficacy. This is suggested by strong downregulation of renal renin,5,7 In a recent randomized controlled trial, paricalcitol reduces left ventricular hypertrophy in stage III/IV CKD patients is currently under investigation in the PRIMO study (ClinicalTrials.gov Identifier: NCT00497146).

Interactions between vitamin D and other RAAS components have been studied as well. Aldosterone acts through the mineralocorticoid receptor, which belongs to the same superfamily of nuclear receptors as the VDR. Therefore, cross talk between these receptors and their agonists could potentially exist, but this has not been studied so far. Mice that are genetically deficient for klotho, a protein associated with downregulation of 1-alpha hydroxylase and, thus, limited production of calcitriol, show excessive levels of calcitriol but also hyperaldosteronism, which is similarly reversed by a vitamin D-deficient diet.13 Although these findings suggest a possible interaction between vitamin D and aldosterone synthesis, it is uncertain whether hyperaldosteronism is a direct consequence of hypervitaminosis D. Data from in vitro studies do not support positive regulation of aldosterone synthesis by vitamin D, as treatment of cultured adrenergic cells with calcitriol reduce aldosterone levels.24 In VDR null mice, although there seems to be a trend toward increased aldosterone levels, the elevation is not significant as compared with wild-type mice,24 which is in contrast with the strong downregulation of renal renin,5 suggesting that the effect on aldosterone may in fact be through renin. Treatment of spontaneous hypertensive rats (SHR) with cholecalciferol also reduces plasma aldosterone levels, but here, also, a direct suppressive effect on renin transcription cannot be excluded.23 Vice versa, aldosterone may potentiate the effects of calcitriol, as demonstrated in cultured renal thick ascending limb cells.26 In this study, calcitriol negatively regulates HCO3− absorption in the rat medullary thick ascending limb, which may contribute to net urine acid and/or calcium excretion. Addition of aldosterone potentiated the effects of calcitriol through an ERK-dependent, non-genomic pathway. This implicates that cross talk between the mineralocorticoid receptor and VDR may indeed be present, and requires further study.

Whether vitamin D modulates the expression of angiotensin II receptors is unknown. The only study on this subject reports that in adipocytes, vitamin D downregulates expression of the AT1 receptor in a dose-dependent manner,27 but, to our knowledge, these findings have never been replicated in other cell types.

In conclusion, both clinical and mechanistic studies suggest that calcitriol, through the VDR, has a negative regulatory role on renin gene transcription. Whether vitamin D also interacts with other RAAS components is unclear. Correcting vitamin D deficiency may have renal and cardiovascular protective effects, at least in part, through suppression of the RAAS. The direct suppressive effect of calcitriol on the renin gene raises the question whether a feedback loop exists, that is, if the RAAS also influences vitamin D metabolism. Recent data suggest that indeed activation of vitamin D, through klotho and 1-alpha hydroxylase, could be affected by angiotensin II.

### POSSIBLE EFFECTS OF THE RAAS ON KLOTHO, FGF-23, AND VITAMIN D

The possible regulation of vitamin D metabolism by the RAAS is less well defined than the opposite regulation of the renin gene by calcitriol. Although there is no evidence that any RAAS component directly influences the enzyme 1-alpha hydroxylase or VDR, indirect effects of angiotensin II on 1-alpha hydroxylase, through klotho and FGF-23, may play a role.

### Negative Regulation of Klotho by Angiotensin II

Accumulating data suggests that angiotensin II negatively regulates the renal expression of klotho.28–31 In an animal model, Mitani et al. demonstrated downregulation of renal klotho expression in response to angiotensin II infusion. Klotho downregulation also followed infusion of angiotensin II in a nonpressor dose.28 The downregulation of klotho was angiotensin II type 1 (AT1) receptor-dependent, since it...
was completely abolished by losartan and not by hydralazine. Intriguingly, subsequent restoration of klotho abundance in the kidney by gene transfer improved angiotensin II-induced proteinuria, suggesting that nonpressor-driven angiotensin II-induced proteinuria, at least in part, depends on loss of klotho.

In cultured tubular epithelial cells, angiotensin II-induced AT1-receptor-mediated downregulation of klotho was confirmed. In a recent elegant study, Yoon et al. demonstrated, in a mouse model, that salt restriction, a well-known RAAS-activating intervention, reduced klotho expression, which was reversed by losartan. The same study revealed that cyclosporin-induced damage associates with downregulation of renal klotho in association with upregulation of renal RAAS activation; addition of losartan completely prevented the loss of klotho expression.

Several other animal models characterized by an activated RAAS, including SHR, noninsulin-dependent diabetic nephropathy (Otsuka Long-Evans Tokushima Fatty rats), and 5/6 nephrectomy, all demonstrate downregulation of renal klotho. The fact that renal klotho expression is also reduced in the DOCA salt rat model, characterized by RAAS suppression and renal damage, also suggests that other factors, such as tubular injury, contribute to downregulation of klotho in renal damage. Studies in patients suggest reduced renal klotho expression per nephron in kidney sections from CKD patients, as compared with control kidneys, but whether this is associated with RAAS activation is unclear. Interestingly, calcitriol has been shown to enhance renal klotho expression in vivo, possibly as a consequence of reduced RAAS activation.

Mechanisms of Klotho Downregulation
The mechanisms of klotho downregulation by angiotensin II are incompletely understood. Although direct negative regulation through the AT1 receptor is possible, other factors, such as oxidative stress, may contribute. Like angiotensin II, oxidative stress itself can cause downregulation of renal klotho. Subsequent administration of a free-radical scavenger prevented klotho downregulation induced not only by oxidative stress but also by infusion of angiotensin. It is well established that angiotensin II influences oxidative stress through the NADPH oxidase system. Conversely, inhibitors of the RAAS ameliorate the production of reactive oxygen species, which could, at least in part, explain the effects of RAAS inhibitors on klotho expression.

Interestingly, TNF alpha converting enzyme (TACE or ADAM17), which is upregulated in the presence of vitamin D deficiency, may be involved in cleavage of the extracellular domain of klotho. Moreover, angiotensin II itself also upregulates TACE, providing another mechanism for klotho downregulation. It may be through this mechanism that even distant inflammation downregulates renal klotho. These preliminary data suggest that klotho function could be affected by vitamin D deficiency through proteolytic activity of TACE, especially under inflammatory conditions.

Consequences of Downregulated Klotho and FGF-23 Resistance
The klotho gene encodes two proteins from five exons: membrane bound klotho (mKlotho; molecular weight 130 kD) and secreted klotho (sKlotho; 80 kD), which is a product of alternative splicing. A third form of klotho, a cleavage product of the extracellular domain of mKlotho, is referred to as cut-Klotho (cKlotho). Although, under physiologic conditions, the klotho gene is expressed only in selected tissues, including distal tubular segments of the kidney, klotho null mice have the phenotype of generalized aging. A recent study demonstrated that klotho deficiency causes vascular calcification in CKD. The similarity between klotho and FGF-23 mice led to the discovery that klotho is mandatory for FGF-23 signaling by modification of the low-affinity FGF receptor (FGFR1), leading to the high-affinity receptor that comprises the membrane-bound FGFR1/klotho complex. Only mKlotho, and not one of the circulating forms, can form an FGF-23 receptor from FGFR1. As a consequence of klotho downregulation, the high-affinity FGFR1/klotho complex is reduced, inducing FGF-23 resistance. Thus, by its effect on klotho, angiotensin II could theoretically be involved in induction of FGF-23 resistance. In CKD, FGF-23 resistance abates fractional excretion of phosphate, leading to further hyperphosphatemia and thus providing another trigger for FGF-23 release. As a consequence of high FGF-23 levels, vitamin D activation is suppressed. Administration of recombinant FGF-23 to normal mice reduces renal expression of 1-alpha hydroxylase and increases renal CYP24A1, resulting in low calcitriol levels; this effect is mediated by extracellular signal-regulated kinase (ERK). Both FGF-23 and klotho null mice display increased expression of 1-alpha hydroxylase. This suggests that klotho, in concert with FGF-23, participates in an inhibitory feedback loop that results in the suppression of calcitriol synthesis. High levels of FGF-23 suppress activation of vitamin D and are associated with progression of CKD, left ventricular mass and geometry, atherosclerosis, and mortality in dialysis patients. Clinical data suggest that the mechanisms underlying the association between FGF-23 and vascular complications are multiple, including suppression of vitamin D activation, reduced fetuin-A levels, and endothelial dysfunction, partially through asymmetrical dimethyl arginine (ADMA). Moreover, higher FGF23 is associated with proteinuria throughout several ranges of CKD independently of levels of active vitamin D.

Besides its role as part of the FGF-23 receptor complex, the β-glucuronidase activity of klotho is important in stabilizing the abundance of the TRPV5 in the apical membrane of tubular cells. Loss of renal klotho in CKD may thus lead to renal calcium loss, providing another impulse for vitamin D activation. In addition, overexpression of klotho provides renoprotection in mouse and rat models of renal damage, suggesting that renal loss of klotho, as observed in CKD, may result in renal damage.

Finally, klotho appears to have distant effects, especially on the vasculature. Although it is possible that the originally described phenotype of premature aging in klotho-deficient mice is the consequence of disturbed regulation of calcium, phosphate, and vitamin D metabolism in the
kidney, several recent reports suggests that klotho has specific functions at distant tissues. Klotho, for example, protects endothelial cells against oxidative-stress induced apoptosis.66,67 An elegant study demonstrated that klotho-deficient mice have endothelial dysfunction, which could be restored by parabiosis with wild-type mice, suggesting that klotho might be involved in nitric oxide synthesis.68 At least part of the beneficial effects of klotho may be mediated by inhibition of insulin/IGF-1 signaling, thereby improving resistance against oxidative stress.69 Recently it was shown that klotho modulates intracellular calcium handling in endothelial cells through the VEGF receptor and TRPC-1, and thus protects these cells from loss of integrity through apoptosis.70 The resemblance of the abovementioned observations with the effects of RAAS activation suggests that a part of the clinical picture as observed in a state of RAAS activation in CKD might in fact be due to klotho deficiency.

**CAN THE VITAMIN D-FGF-23-KLOTHO AXIS BE MONITORED AND TARGETED?**

The data summarized here suggest a relationship between RAAS activation, low renal klotho levels, and high FGF-23 levels in CKD patients, all of which associate with adverse outcomes. Future studies are needed to address whether adequate renal klotho, as measured, for instance, by fractional phosphate excretion, vitamin D, or FGF23 levels, (possibly) circulating klotho, or a combination of these factors, could be a therapeutic target. Targeting klotho deficiency in CKD, which could be achieved by optimizing RAAS blockade and correction of vitamin D deficiency, may further reduce cardiovascular disease and progression of kidney injury.

**Conclusions**

Emerging evidence demonstrates the negative regulation of the RAAS by calcitriol, providing renoprotective effects of vitamin D analogues in addition to RAAS blockade in CKD. A growing number of studies support suppression of 1-alpha hydroxylase by angiotensin II through renal downregulation of klotho and subsequent FGF-23 resistance (summarized in Figure 1, left panel). Besides its effects on vitamin D metabolism, high levels of FGF-23 or FGF-23 resistance, due to klotho deficiency, are associated with endothelial dysfunction, cardiovascular morbidity and mortality, and progression of CKD.71 In CKD, loss of capacity for excreting phosphate by reduced nephron mass and loss of klotho due to RAAS activation and tubulointerstitial damage both further enhance circulating

![Figure 1](image-url)
levels of FGF-23 and reduce levels of active vitamin D (Figure 1, right panel). Further derangement of these interconnected axes may well contribute to the cardiovascular complications of CKD.

RAAS inhibition and supplementation of vitamin D deficiency are well-established interventions for prevention of progressive renal function loss and its extrarenal complications, as recommended by current guidelines72 (http://www.nice.org.uk). Interestingly, these interventions appear to share a part of their beneficial effects by interrupting the vicious cycle of increasing FGF23 resistance due to klotho deficiency. However, the protection against renal progression and its extrarenal complications by current therapy is far from complete, prompting for improvement of treatment strategies. Currently, management of blood pressure and proteinuria by RAAS blockade and vitamin D supplementation are independent components of the treatment regimen. Their separate and combined impact on the FGF-23-klotho axis is not monitored, nor is it a treatment target. It would be attractive to hypothesize that targeting optimization of this axis, particularly optimal levels of renal klotho, could enhance therapeutic efficacy, either by adapting titration strategies for currently available drugs or by novel agents.

DISCLOSURES
Dr. De Borst is supported by personal development grants from the Dutch Kidney foundation (KJPB.08.07) and the University Medical Center Groningen (Mandema stipend), and by the European grants from the Dutch Kidney foundation (KJPB.08.07) and the University Medical Center Groningen (Mandema stipend), and by the European.

REFERENCES


